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S U M M A R Y
Hepatitis C virus (HCV) infection is a worldwide concern. Knowledge of the HCV genotype is clinically
important because it predicts the rate of response to therapy and guides the treatment duration.
Moreover, it allows molecular epidemiology to be performed. To our knowledge, the prevalence of HCV
genotypes has been assessed only once in Albania, using a line probe genotyping assay. We determined
HCV genotypes by population sequencing of HCV-infected patients in Tirana, Albania. HCV genotype and
sequence analyses were performed for serum samples collected from January 2011 through May 2012
from 61 HCV-seropositive patients using population sequencing of the NS3 protease gene and
alternatively the NS5b gene and the 50 untranslated region (UTR). HCV RNA was retrieved from the blood
samples of 50 patients. The HCV NS3 protease gene was sequenced for 28 patients and NS5b and/or
50UTR fragments were sequenced for an additional 22 patients. The predominant genotype was 1b in 25
patients (50%), followed by genotypes 2c, 4a, 3a, and 1a in 18%, 14%, 8%, and 6% of cases, respectively. Best
matches for these HCV RNAs in GenBank were obtained in different countries worldwide. One NS3
protease naturally harbored an amino acid conferring minor drug resistance to newly available HCV
protease inhibitors. In conclusion, HCV-1b was predominant in the present Albanian population, as in
southeastern Europe.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Hepatitis C virus (HCV) genotype identiﬁcation is clinically
important because it predicts the rate of sustained virological
response and contributes to the determination of treatment
duration.1 In addition, HCV genotyping is a powerful tool to
describe HCV epidemiology.2 Very few data exist on HCV infection
in Albania. The prevalence of HCV antibodies was found to be 0.07%
in blood donors, 2.3% and 0.3% in Albanian emigrant populations in
Greece and southern Italy, respectively, and 14% and 11% in 1995
and 2005, respectively, for patients with viral and/or alcoholic liver
disease at the University Hospital of Tirana, the capital city.3–5 To
our knowledge, HCV molecular epidemiology has been assessed* Corresponding author. Tel.: +33 491 385 519.
E-mail address: philippe.colson@ap-hm.fr (P. Colson).
1201-9712       2013 The Authors. Published by Elsevier Ltd on behalf of International Soci
http://dx.doi.org/10.1016/j.ijid.2013.08.015only once in Albania, using a line probe genotyping assay. We
determined HCV genotype prevalence in Albanian patients by
sequencing.
2. Materials and methods
Serum samples collected from 61 HCV-infected patients from
January 2011 through May 2012 at the University Hospital Center
(UHC) of Tirana, Albania, were analyzed. The HCV-infected patients
were mostly on the following wards: hepatology (n = 22),
nephrology including dialysis (n = 12), infectious diseases (n = 9),
pediatrics (n = 4), and hematology (n = 2). Thirty-nine patients
were men (64%). HCV genotyping was performed using in-house
assays targeting initially the NS3 protease gene (543 nucleotides),2
then, in the case of negative PCR ampliﬁcation of this gene, a 195-
nucleotide-long fragment of the NS5b gene or an approximately
200-nucleotide-long region of the 50 untranslated region (UTR).2
HCV sequences were retrieved using a 3130XL Genetic Analyzer
(Applied Biosystems, Branchburg, NJ, USA) then analyzed using
Seqscape v2.5 (Applied Biosystems). HCV RNA sequences wereety for Infectious Diseases. Open access under CC BY-NC-ND license.
Figure 1. Phylogenetic tree based on partial sequences of the NS3 protease gene of the HCV genome (513 nucleotides; nucleotides 3420–3932 in reference to HCV genome
accession number AF011751). HCV sequences obtained in the present study are indicated with the black boxes. Sequences with the highest BLAST score recovered from the
NCBI GenBank nucleotide sequence database (indicated in boldface, underlined and labeled with BBH, GenBank accession number, country, and year of collection or
submission) for sequences obtained in the present study have been incorporated in the phylogeny reconstruction in addition to sequences with known genotypes and
subtypes (http://www.ncbi.nlm.nih.gov/projects/genotyping/view.cgi?db=3). Nucleotide alignments were performed using ClustalX v2.0 (http://www.clustal.org/
download/current/). The tree was constructed using MEGA v5.0 software (http://www.megasoftware.net/) and the neighbor-joining method. Branches with bootstrap
values 50%, obtained from 1000 resamplings of the data, are labeled on the tree. The HCV sequence EF108306 (genotype 7) was used as an outgroup. The scale bar indicates
the number of nucleotide substitutions per site. (BBH, best BLAST hit; Ref, reference sequence.).
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Figure 2. Phylogenetic tree based on partial sequences of the NS5b encoding gene of the HCV genome (195 nucleotides; nucleotides 8287–8481 in reference to HCV genome
accession number AF011751). HCV sequences obtained in the present study are indicated with the black boxes. Sequences with the highest BLAST score recovered from the
NCBI GenBank nucleotide sequence database (indicated in boldface, underlined and labeled with BBH, GenBank accession number, country, and year of collection or
submission) for sequences obtained in the present study have been incorporated in the phylogeny reconstruction in addition to sequences with known genotypes and
subtypes (http://www.ncbi.nlm.nih.gov/projects/genotyping/view.cgi?db=3). Nucleotide alignments were performed using ClustalX v2.0 (http://www.clustal.org/
download/current/). The tree was constructed using MEGA v5.0 software (http://www.megasoftware.net/) and the neighbor-joining method. Branches with bootstrap
values 50%, obtained from 1000 resamplings of the data, are labeled on the tree. The HCV sequence EF108306 (genotype 7) was used as an outgroup. The scale bar indicates
the number of nucleotide substitutions per site. (BBH, best BLAST hit; Ref, reference sequence.).
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current/) with sequences from the reference set of the NCBI
genotyping tool (http://www.ncbi.nlm.nih.gov/projects/genotyp-
ing/view.cgi?db=3) and the two best matches obtained through
BLAST searches against the NCBI sequence database for each
sequence recovered here. Pairwise nucleotide similarities were
generated using BioEdit (http://www.mbio.ncsu.edu/bioedit/
page2.html). Phylogeny reconstructions were performed using
MEGA v5 (http://www.megasoftware.net/).
3. Results
HCV RNA was obtained from 50 blood samples, PCR ampliﬁca-
tion being negative in 11 cases. HCV NS3 protease sequences were
obtained for 28 sera (Figure 1) and the NS5b gene fragment
(Figure 2) and 50UTR were obtained for 18 and four additional sera,
respectively. The predominant genotype was 1b, found in 25
patients (50%). Other genotypes, in decreasing prevalence, were
genotype 2c (n = 9, 18%), 4a (n = 7, 14%), 3a (n = 4, 8%), 1a (n = 3, 6%),
and 2a and 4d (n = 1, 0.2% each). Best BLAST matches for HCV-1b
had been recovered in the USA, France, Switzerland, the UK, Brazil,
Australia, and Japan (Figures 1 and 2). Best matches for HCV-2c had
been obtained in Japan, Argentina, Italy, the UK, and France, while
those for HCV-4a had been obtained in Egypt, Cyprus, and France.
HCV-1b NS3 and NS5b sequences from the present study
showed a mean  standard deviation identity of 91.3  1.6% and
94.2  2.2%, respectively. HCV-1b NS3 RNA from two patients
(numbers 860 and 639) were clustered together and showed 98.8%
identity (Figure 1). These sequences had been recovered in
nephrology and dialysis units. In addition, HCV-1b NS5b RNA from
three patients in a pediatrics unit (numbers 623, 188 and 290) were
clustered and showed 97.5–99.0% identity, and HCV-4a RNA from
four patients including three dialysis patients (numbers 33p, 839,
795, and 323) were clustered and showed 97.0–99.5% identity.
Overall, ﬁve of eight patients (62%) sampled in the dialysis ward were
infected with HCV-4a. Of note, amino acid substitution V55A within
the HCV NS3 protease was observed in one patient naive to anti-HCV
therapy (number 369) and infected with HCV-1a.
4. Discussion
To our knowledge, we have provided the ﬁrst HCV sequences
from patients in Albania. Half of these patients were infected with
HCV-1b. In a previous study conducted on 18 patients with chronic
liver diseases in Tirana using a line probe genotyping assay, HCV-
1b was identiﬁed in 11 cases (61%), then HCV-2a/2c and HCV-3a
were identiﬁed in ﬁve and two patients, respectively.5 This
distribution of HCV genotypes is similar to that observed here.
In addition, the predominance of HCV-1b has been reported in
other southeastern European countries, including Greece, Serbia,
Montenegro, Slovenia, Croatia, and Bosnia and Herzegovina.6–10
(http://hcv.lanl.gov/components/sequence/HCV/geo/geo.comp).
Best matches for HCV RNA obtained here were obtained in multiplecountries on the ﬁve continents, but not in southeastern Europe,
apart from Cyprus. This ﬁnding may be explained by the small
number of HCV sequences available from southeastern Europe,
especially when regarding the NS3 protease region.
The population studied here may not be fully representative of
that of HCV-infected patients in Albania. Notably, only a few
patients likely acquired HCV through intravenous drug use, as this
population is managed in other centers. In one HCV-1a-infected
patient, amino acid 55A was observed within the NS3 protease in
the absence of any prior anti-HCV therapy. The HCV NS3-V55A
substitution was associated with minor drug resistance to linear
HCV NS3 protease inhibitors and compromised viral ﬁtness.11
Further studies, conducted on larger and different populations and
in different regions, are needed to strengthen knowledge on HCV
genotypes that circulate in Albania.
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